Review Proposal - March 2008
Review of NICE Technology Appraisal Guidance No 91; paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for ovarian cancer (advanced) - 2nd line
The Institute has carried out a search for information relevant to this appraisal, and has found that to the best of its knowledge, no new evidence has been published that would have a material effect on the original guidance.
However, we are aware that new evidence relevant to this review will emerge in the next couple of years and relevant clinical studies will be reporting during 2009. Consequently we propose that the decision to review the original guidance be deferred until November 2009. This will allow this research to be available to inform the decision.
In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial.
Please note all comments received will be published on the Institute's website when a decision has been taken.
For a full list of the organisations we have contacted, please click here.
5 March 2008
This page was last updated: 30 March 2010